134 results
8-K
EX-1.1
GRTS
Gritstone Bio Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:23pm
than three years prior to the date hereof. The Company and its subsidiaries have not received any written notice that the sponsoring or responsible
8-K
EX-4.2
GRTS
Gritstone Bio Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:23pm
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules
8-K
EX-4.1
GRTS
Gritstone Bio Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:23pm
with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent … ) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. In addition, a determination as to any
424B5
GRTS
Gritstone Bio Inc
2 Apr 24
Prospectus supplement for primary offering
5:20pm
colorectal cancer
Gilead is responsible for conducting a Phase 1 clinical trial
National Cancer Institute (NCI) is responsible for conducting a Phase 1 … , if any, responsible for overseeing such composite currency;
the designation of the currency, currencies or currency units in which payment of principal
424B5
dok4g2za
1 Apr 24
Prospectus supplement for primary offering
4:43pm
UPLOAD
yqulod
27 Dec 23
Letter from SEC
12:00am
8-K
EX-99.1
qokhwa1 ets4oo
8 Nov 23
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
4:06pm